These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19047598)

  • 1. Treatment of community-acquired pneumonia.
    Low DE
    CMAJ; 2008 Dec; 179(12):1245-6. PubMed ID: 19047598
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia.
    Olson G; Davis AM
    JAMA; 2020 Mar; 323(9):885-886. PubMed ID: 32027358
    [No Abstract]   [Full Text] [Related]  

  • 3. β-lactam monotherapy is non-inferior to combination treatment for community-acquired pneumonia.
    Burki TK
    Lancet Respir Med; 2015 May; 3(5):347. PubMed ID: 25892353
    [No Abstract]   [Full Text] [Related]  

  • 4. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
    Restrepo MI; Frei CR
    Am J Med; 2010 Apr; 123(4 Suppl):S39-46. PubMed ID: 20350634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.
    Vardakas KZ; Siempos II; Grammatikos A; Athanassa Z; Korbila IP; Falagas ME
    CMAJ; 2008 Dec; 179(12):1269-77. PubMed ID: 19047608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics for Community-Acquired Pneumonia in Adults.
    Nie W; Li B
    N Engl J Med; 2015 Aug; 373(7):684. PubMed ID: 26267640
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotics for Community-Acquired Pneumonia in Adults.
    van Werkhoven CH; Postma DF; Bonten MJ
    N Engl J Med; 2015 Aug; 373(7):684-6. PubMed ID: 26267636
    [No Abstract]   [Full Text] [Related]  

  • 11. Antibiotics for Community-Acquired Pneumonia in Adults.
    van der Eerden MM
    N Engl J Med; 2015 Aug; 373(7):683. PubMed ID: 26267637
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibiotics for Community-Acquired Pneumonia in Adults.
    Piszczek J; Partlow E
    N Engl J Med; 2015 Aug; 373(7):683-4. PubMed ID: 26267638
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibiotics for Community-Acquired Pneumonia in Adults.
    Kinsella J; Kearns RJ
    N Engl J Med; 2015 Aug; 373(7):684. PubMed ID: 26267639
    [No Abstract]   [Full Text] [Related]  

  • 14. [Community acquired pneumonia: antibiotic monotherapy is not inferior to combination therapy].
    Kern WV
    Dtsch Med Wochenschr; 2015 Jun; 140(13):964. PubMed ID: 26115125
    [No Abstract]   [Full Text] [Related]  

  • 15. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
    File TM
    J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
    Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
    Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does empirical therapy with a fluoroquinolone or the combination of a β-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?
    Ruhe J; Mildvan D
    Infect Dis Clin North Am; 2013 Mar; 27(1):115-32. PubMed ID: 23398869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia.
    van der Eerden MM; Boersma WG
    Eur Respir J; 2009 Aug; 34(2):521. PubMed ID: 19648530
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.